Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: a case report.

Candler T, McGregor D, Narayan K, Moudiotis C, Burren CP

Journal of pediatric endocrinology & metabolism : JPEM1 Jul 2020Cited by 14 (Europe PMC)

PMID32447330DOI10.1515/jpem-2019-0389PepBankPUB-32447330

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome
In an adolescent girl with Prader-Willi syndrome and diabetes, liraglutide plus metformin did not improve glucose levels.
In plain wordsIn one girl with Prader-Willi syndrome and diabetes, liraglutide with metformin did not improve blood sugar.
Peptide
Liraglutide
Outcome
No significant changeGlucose levels on liraglutide plus metformin
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Liraglutide (GLP-1 agonist) and Metformin did not improve glucose levels nor her weight.
1 context sentence(design, population, supporting numbers)
Summary · context
We present a prepubertal girl with PWS who developed diabetes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3244733001
02HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome
In an adolescent girl with Prader-Willi syndrome and diabetes, liraglutide plus metformin did not improve weight.
In plain wordsIn one girl with Prader-Willi syndrome and diabetes, liraglutide with metformin did not improve weight.
Peptide
Liraglutide
Outcome
No significant changeWeight on liraglutide plus metformin
Study
n = 1
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Liraglutide (GLP-1 agonist) and Metformin did not improve glucose levels nor her weight.
1 context sentence(design, population, supporting numbers)
Summary · context
We present a prepubertal girl with PWS who developed diabetes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3244733002
03HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome
In an adolescent girl with Prader-Willi syndrome and diabetes, liraglutide plus empagliflozin was followed by rapid normalisation of blood glucose.
In plain wordsIn one girl with Prader-Willi syndrome and diabetes, liraglutide with empagliflozin was followed by quick normal blood sugar.
Peptide
Liraglutide
Outcome
DecreaseBlood glucose on liraglutide plus empagliflozin
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Liraglutide and Empaglifozin (SGLT-2 inhibitor) therapy used in combination were well tolerated and demonstrated rapid normalisation of blood glucose and improvement in her HbA1c to within target (48 mmol/mol) which was sustained after 6 months of treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
We present a prepubertal girl with PWS who developed diabetes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3244733003
04HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome
In an adolescent girl with Prader-Willi syndrome and diabetes, HbA1c improved to within target, sustained after 6 months, on liraglutide plus empagliflozin.
In plain wordsIn one girl with Prader-Willi syndrome and diabetes, HbA1c reached the target range and stayed there for 6 months on liraglutide with empagliflozin.
Peptide
Liraglutide
Outcome
DecreaseHbA1c on liraglutide plus empagliflozin
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c
48 mmol/mol
liraglutide plus empagliflozin
Source sentences
Summary
Liraglutide and Empaglifozin (SGLT-2 inhibitor) therapy used in combination were well tolerated and demonstrated rapid normalisation of blood glucose and improvement in her HbA1c to within target (48 mmol/mol) which was sustained after 6 months of treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
We present a prepubertal girl with PWS who developed diabetes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3244733004
05HumanNot a test of Liraglutide aloneCase report or seriesSafety outcome
In an adolescent girl with Prader-Willi syndrome and diabetes, liraglutide plus empagliflozin was well tolerated.
In plain wordsIn one girl with Prader-Willi syndrome and diabetes, liraglutide with empagliflozin was well tolerated.
Peptide
Liraglutide
Outcome
No significant changeTolerability of liraglutide plus empagliflozin
Study
n = 1
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
Liraglutide and Empaglifozin (SGLT-2 inhibitor) therapy used in combination were well tolerated
1 context sentence(design, population, supporting numbers)
Summary · context
We present a prepubertal girl with PWS who developed diabetes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3244733005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.